Search

Corvus Pharmaceuticals Inc

Gesloten

14.4 -1.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.33

Max

14.51

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.3M

-18M

EPS

-0.19

Werknemers

37

EBITDA

-5.3M

-17M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+105% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

57M

1.2B

Vorige openingsprijs

15.84

Vorige sluitingsprijs

14.4

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 sep 2026, 23:56 UTC

Correlated Moves

Macy's Inc shares are lower in after-market trading, influenced by a decline in Kohl's Corp and broader retail sector challenges.

4 sep 2026, 23:56 UTC

Southern Co. shares traded roughly flat in after-market hours, remaining below their 20-day moving average and near the lower end of their one-month range.

4 sep 2026, 23:56 UTC

Redwood Trust shares rose in after-market trading, amid rising Treasury yields and stable unemployment. The stock remains below its 20-day moving average.

4 sep 2026, 23:55 UTC

Mastercraft Boat Holdings Inc shares are higher in after-market hours. No specific news was identified to explain the movement.

4 sep 2026, 23:55 UTC

TE Connectivity PLC shares are higher in after-market trading. No specific company news was identified to explain this movement.

4 sep 2026, 23:55 UTC

Ameriprise Financial Inc shares are higher in after-market trading, influenced by stable labor market data and expectations for an interest rate hike.

4 sep 2026, 23:55 UTC

Incyte Corp shares are higher in after-market hours, reaching an early peak before settling back. No specific news was identified to explain the movement.

4 sep 2026, 23:55 UTC

Fastenal Co. shares moved higher in after-market trading, recovering from earlier losses amid rising Treasury yields and steady unemployment data.

4 sep 2026, 23:51 UTC

International Bancshares Corp. shares remained roughly flat during after-market hours, following four consecutive sessions of higher performance. No specific news was identified.

4 sep 2026, 23:51 UTC

Cytokinetics Inc shares are higher in after-market trading, reaching their highest cumulative return of the day, despite no specific news driving the move.

4 sep 2026, 23:51 UTC

Tecnoglass Inc shares are trading higher in after-market hours, marking five consecutive sessions of gains. No specific news was identified to explain the movement.

4 sep 2026, 23:51 UTC

CGI Inc shares are lower in after-market hours, continuing a decline since Friday's close. The stock remains significantly below its 20-day moving average.

4 sep 2026, 23:51 UTC

CME Group Inc shares are higher in after-market hours, reflecting strong performance as they approach the upper end of their one-month trading range.

4 sep 2026, 23:51 UTC

Axon Enterprise Inc shares are trading higher in after-market hours. No specific news was identified to explain this movement.

4 sep 2026, 23:51 UTC

Kohls Corp shares are lower in after-market hours amid weak trading and mixed economic signals, including rising unemployment and slowing wage growth.

4 sep 2026, 23:51 UTC

Nextera Energy Inc shares are lower in after-market hours, breaking a recent trend of higher daily closes amid a slight uptick in unemployment rates.

4 sep 2026, 23:51 UTC

EPR Properties shares are higher in after-market hours, reflecting unusual strength despite no specific company news amid mixed economic signals and interest rate expectations.

4 sep 2026, 23:51 UTC

Tapestry Inc shares are higher in after-market hours, recovering from an early dip. The stock remains below its 20-day moving average.

4 sep 2026, 23:51 UTC

ECB Set to Announce Deposit Facility Rate Hike Amid Inflation Concerns and Geopolitical Tensions on September 10, 2026.

4 sep 2026, 23:50 UTC

Wesco International Inc shares are higher in after-market hours, continuing a trend of recent gains and unusual trading activity noted earlier in the session.

4 sep 2026, 23:50 UTC

Weyerhaeuser Co shares are higher in after-market trading, reflecting an increase since Friday's close, despite remaining below the 20-day moving average.

4 sep 2026, 23:46 UTC

Antero Midstream Corp. shares showed little change during after-market hours, fluctuating within a narrow range and remaining above the 20-day moving average.

4 sep 2026, 23:46 UTC

Correlated Moves

US Bancorp shares are lower in after-market trading amid mixed macroeconomic signals and a decline in Live Oak Bancshares, reflecting broader market sentiments.

4 sep 2026, 23:46 UTC

Biogen Inc shares are lower in after-market hours, with no specific news driving the decline. Broader economic signals are contributing to market uncertainty.

4 sep 2026, 23:46 UTC

Enovix Corp shares are higher in after-market trading, though no specific news was identified to explain the movement. Broader market dynamics influenced investor sentiment.

4 sep 2026, 23:45 UTC

Hershey Co. shares gained in after-market trading, reflecting routine performance amid broader market dynamics, despite earlier fluctuations after Friday's close.

4 sep 2026, 23:45 UTC

First American Financial shares higher in after-market trading, reflecting broader market movements amid shifting expectations for interest rates and recent economic data.

4 sep 2026, 23:45 UTC

Iron Mountain Inc is trading lower in after-market hours, with no specific news identified. The stock remains near its one-month low and below its 20-day moving average.

4 sep 2026, 23:45 UTC

Social Media

NIO Inc. CEO William Li discussed "operational quality" in a closed-door meeting. Shares traded roughly flat during after-market hours following the discussion.

4 sep 2026, 23:45 UTC

Lucid Group Inc. shares are trading lower in after-market hours, continuing a trend of weakness amid broader market declines and remaining below the 20-day moving average.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

105% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD  105%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat